aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference
aTyr Pharma (Nasdaq: LIFE) has announced that Sanjay S. Shukla, M.D., the President and CEO, will present a corporate overview at the 2022 Jefferies Healthcare Conference in New York from June 8 to 10, 2022. Dr. Shukla's presentation is scheduled for June 8 at 10:00 AM EDT. The company will conduct one-on-one meetings with registered investors during the conference. A webcast of the presentation will be available on the company’s website, with a replay accessible for at least 30 days following the event.
- None.
- None.
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines from its proprietary tRNA synthetase biology platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the 2022 Jefferies Healthcare Conference, which is scheduled to take place June 8 – 10, 2022, in New York, NY.
Dr. Shukla will present on Wednesday, June 8, 2022, at 10:00am EDT.
In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference. A webcast of the event will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the event, a replay of the presentation will be available on the aTyr website for at least 30 days.
About aTyr
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines from its proprietary tRNA synthetase biology platform. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease. For more information, please visit http://www.atyrpharma.com.
| Contact: |
| Ashlee Dunston |
| Director, Investor Relations and Corporate Communications |
| adunston@atyrpharma.com |
FAQ
What is aTyr Pharma's presentation schedule for the Jefferies Healthcare Conference?
Where can I watch aTyr Pharma's conference presentation?
What is the focus of aTyr Pharma's research and development?
When is the Jefferies Healthcare Conference in 2022?
What is the stock symbol for aTyr Pharma?
